StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Zepatier (elbasvir and grazoprevir by Year

Zepatier (elbasvir and grazoprevir — HCV, legacy) — Worldwide reported growth YoY (%) (%)

Merck Zepatier (elbasvir and grazoprevir: -55.0% in FY2020, down 36.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, FY2020
-55.0%
Period ended Dec 31, 2020
Change on a year earlier
-36.0 pts
-19.0% in FY2019
History
4 years
Since FY2017
Sources
4
Documents cited below

Where the FY2020 figure comes from

“|| Zepatier | 55 | 39 | 28 | 45 | 167 | 114 | 108 | 83 | 66 | 370 | -32 | -32 | -55 | -54”

Source: Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗

Reported in Form 8-K Table 3 / 3a / 3b Product Sales.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZepatier (elbasvir and grazoprevir — HCV, legacy) — Worldwide reported growth YoY (%) (%)Year on yearSource
FY2020Dec 31, 2020-55.0%-36.0 ptsForm 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
FY2019Dec 31, 2019-19.0%+54.0 ptsForm 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2018Dec 31, 2018-73.0%-272.0 ptsForm 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
FY2017Dec 31, 2017199.0%–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Cite this data

StockData. (2026). Merck Zepatier (elbasvir and grazoprevir (%), annual FY2017–FY2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zepatier-ww-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.